Interestingly, anti-TNF-α therapy has been associated also with the new onset or exacerbation of ILD mainly in patients affected by RA, being the TNF-α, a vital cytokine implicated in the development of pulmonary fibrosis [43, 44]. This evidence concerns the gene TNF and pulmonary fibrosis.